HealthScience
Belgian Combo Therapy Halves Type 1 Diabetes Risk in Study
Belgian researchers from VUB and KU Leuven show a combination therapy targeting both immunity and beta cells halves type 1 diabetes risk in mice.
—4 min read
Tag
2 articles
Belgian researchers from VUB and KU Leuven show a combination therapy targeting both immunity and beta cells halves type 1 diabetes risk in mice.
VUB and KU Leuven researchers show combining immunotherapy with beta cell protection significantly slows type 1 diabetes in preclinical trials.